Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989266 | 0.85 | MAPK14 (0.52) | MAPK14CYP3A4 | |
| SCHEMBL989296 | 0.77 | MAPK14 (0.52) | MAPK14CYP3A4 | |
| SCHEMBL3989284 | 0.75 | MAPK14 (0.43) | MAPK14PTGESCYP2C9 | |
| SCHEMBL990606 | 0.75 | APP (0.50) | MAPK14CYP2C9CYP3A4 | |
| SCHEMBL3989359 | 0.74 | MAPK14 (0.57) | MAPK14PTGESCYP2C9 | |
| SCHEMBL3997659 | 0.72 | MAPK14 (0.48) | MAPK14CYP3A4 | |
| SCHEMBL990149 | 0.70 | MAPK14 (0.64) | MAPK14CYP3A4 | |
| SCHEMBL8793341 | 0.68 | MAPK14 (0.63) | MAPK14CYP2C9CYP3A4 | |
| SCHEMBL8791756 | 0.68 | MAPK14 (0.55) | MAPK14PTGESCYP2C9CYP3A4 | |
| SCHEMBL8793042 | 0.68 | MAPK14 (0.56) | MAPK14PTGESCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | MAPK14 341/4885PTGES 3654/4885CYP2C9 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.